|
|
|
| Clinical Effect of Yangzhengxiaoji Capsule Combined with Pemetrexide and Carboplatin in the Treatment of EGFR Wild-type or Unknown Metastatic Lung Adenocarcinoma |
| ZHAN Juan, FU Jian-guo, SONG Min,et al |
| Department of Oncology, Zhongshan Hospital Affiliated to Xiamen University,Xiamen, Fujian,361004, China |
|
|
|
|
Abstract 【Objective】To investigate the clinical effect of Yangzhengxiaoji capsule combined with pemetrexide and carboplatin in the treatment of EGFR wild-type or unknown metastatic lung adenocarcinoma. 【Methods】 The clinical data of 48 patients with EGFR wild type or unknown status of metastatic lung adenocarcinoma were selected. The patients were randomly divided into observation group and control group with 24 cases in each group.The observation group was treated with Yangzhengxiaoji capsule combined with pemetrexide and carboplatin chemotherapy, while the control group was treated with the placebo of Yangzhengxiaoji capsule combined with pemetrexide and carboplatin chemotherapy.Adverse reactions were observed in the two groups, and the clinical efficacy and quality of life (QOL) were evaluated after 2 cycles. 【Results】There was no complete remission of (CR) in both groups.The objective effective rate (ORR) of the observation group was 33. 3%(8/24).The disease control rate (DCR) was 83.3% (8/24), the ORR of the control group was 25.5%(6/24), DCR=66.7%(16/24), there was no significant difference between the two groups (mean P>0.05).The main adverse reactions in the two groups were bone marrow suppression, digestive tract reaction and fatigue, most of which were grade 1 or 2. No grade 4 or 5 adverse reactions occurred in both groups.The incidence of neutropenia, nausea, vomiting, liver function damage and fatigue in the observation group was significantly lower than that in the control group (P<0.05).【Conclusion】 Yangzhengxiaoji capsule combined with pemetrexide and carboplatin in the treatment of EGFR wild-type or unknown senile metastatic lung adenocarcinoma has a good clinical effect, can significantly reduce or alleviate the adverse reactions associated with chemotherapy, and can significantly improve and stabilize the symptoms of patients,improve the quality of life.Thus,it is worth popularizing in clinic.
|
|
Received: 07 August 2018
|
|
|
|
|
|
[1] 邹小农,贾漫漫,王鑫,等. 中国肺癌和烟草流行及控烟现状[J].中国肺癌杂志, 2017, 20 (8): 505-510.
[2] Mok TS,Wu YL, Thongprasert S,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].N Engl J Med,2009, 361: 947-957.
[3] 毕俊芳,李雪松,陈亦伟,等. 养正消积胶囊治疗恶性肿瘤临床和实验研究近况[J].现代中西医结合,2015,24(33): 3757-3759.
[4] 石远凯,孙燕. 临床肿瘤内科手册[M]. 第6版.北京:人民卫生出版社,2015: 136.
[5] Langendijk JA, Aaronson NK, De Jong JMA, et al. Prospective study on quality of life before and after radical radiotherapy in Non-Small-Cell lung cancer[J].J Clin Oncol,2001,19(8): 2123-2133.
[6] Paz-Ares L, De Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer[J].J Clin Oncol,2013,31: 2895-2902.
[7] 束家和,周荣耀,吴丽英,等. 养正消积胶囊联合化疗治疗中晚期非小细胞肺癌35例临床观察[J].世界中医药,2013,4(8):465-468.
[8] 邢力刚,赵汉玺,李贵新,等. 晚期肺癌养正消积胶囊联合化疗临床对照研究[J].中华肿瘤防治杂志,2014,21(5):384-386.
[9] Bouazza YB, Chiairi I, EI Kharbouchi O, et al. Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review[J].Lung Cancer,2017,113 (11): 140-151. |
|
|
|
2018, Vol. 35 
